Intelligence Feed event · Macro · 2026-10-12

    BridgeBio Reports Positive Phase 3 CALIBRATE Trial Data for Encaleret

    Question

    BridgeBio Reports Positive Phase 3 CALIBRATE Trial Data for Encaleret

    Direct answer

    BridgeBio announced positive topline results from the Phase 3 CALIBRATE study evaluating encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1). The trial demonstrated that 91% of treated patients achieved normalization of parathyroid hormone (PTH) levels compared to 0% on conventional therapy, alongside 100% participant-reported symptom improvement.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “BridgeBio Reports Positive Phase 3 CALIBRATE Trial Data for Encaleret”, revision 1, evidence through 2026-10-12. https://marketontology.com/market-events/2026-10-12/bridgebio-reports-positive-phase-3-calibrate-trial-data-for-encaleret-c3c984

    MACRO
    BridgeBio Reports Positive Phase 3 CALIBRATE Trial Data for Encaleret
    BridgeBio announced positive topline results from the Phase 3 CALIBRATE study evaluating encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1). The trial demonstrated that 91% of treated patients achieved normalization of parathyroid hormone (PTH) levels compared to 0% on conventional therapy, alongside 100% participant-reported symptom improvement.
    BBIO
    Impact
    73
    OCT 12
    SIG
    90%
    BBIO
    BridgeBio Reports Positive Phase 3 CALIBRATE Trial Data for Encaleret
    BridgeBio announced positive topline results from the Phase 3 CALIBRATE study evaluating encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1). The trial demonstrated that 91% of treated patients achieved normalization of parathyroid hormone (PTH) levels compared to 0% on conventional therapy, alongside 100% participant-reported symptom improvement.
    → Statistically significant Phase 3 primary endpoint achievement derisks commercial approval pathways, directly impacting biotechnology valuation multiples.
    Impact
    BridgeBio announced positive topline results from the Phase 3 CALIBRATE study evaluating encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1). The trial demonstrated that 91% of treated patients achieved normalization of parathyroid hormone (PTH) levels compared to 0% on conventional therapy, alongside 100% participant-reported symptom improvement.
    Affected
    BBIO
    Transmission
    Statistically significant Phase 3 primary endpoint achievement derisks commercial approval pathways, directly impacting biotechnology valuation multiples.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BBIOpipeline commercialization derisking and cash flow revaluationUp1-5dPositive Phase 3 CALIBRATE trial results for encaleret showing 91% PTH normalization.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    BBIOUpdisagreed65.75 2026-10-12-3.73%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month